Perrigo FY 1995 sales increase 7% to $717.1 mil., following 10% gain in fourth quarter.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO FY 1995 SALES INCREASE 7.1% TO $717.1 MIL. for the year ended June 30. Sales in the fourth quarter rose 10% to $174.4 mil. As expected, the company's analgesic sales continued to be soft into the final quarter, Perrigo noted. The company has cited increased competition in the analgesics market due, in part, to Procter & Gamble's launch of Aleve as well as a mild cold and flu season as negatively affecting its sales
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.